These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38641183)

  • 1. Lymph node targeting strategy using a hydrogel sustained-release system to load effector memory T cells improves the anti-tumor efficacy of anti-PD-1.
    Cui H; Zhao YY; Han YH; Lan Z; Zou KL; Cheng GW; Chen H; Zhong PL; Chen Y; Ma LM; Chen TK; Yu GT
    Acta Biomater; 2024 May; 180():423-435. PubMed ID: 38641183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
    Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
    Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy.
    Liu Z; Yu Z; Chen D; Verma V; Yuan C; Wang M; Wang F; Fan Q; Wang X; Li Y; Ma Y; Wu M; Yu J
    Cancer Commun (Lond); 2022 Oct; 42(10):971-986. PubMed ID: 35962977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy.
    van Pul KM; Fransen MF; van de Ven R; de Gruijl TD
    Front Immunol; 2021; 12():643291. PubMed ID: 33732264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.
    Thomas SN; Vokali E; Lund AW; Hubbell JA; Swartz MA
    Biomaterials; 2014 Jan; 35(2):814-24. PubMed ID: 24144906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.
    Han BJ; Murphy JD; Qin S; Ye J; Uccello TP; Garrett-Larsen J; Belt BA; Prieto PA; Egilmez NK; Lord EM; Linehan DC; Mills BN; Gerber SA
    Immunol Invest; 2020 Oct; 49(7):808-823. PubMed ID: 32498585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yeast-derived nanoparticles remodel the immunosuppressive microenvironment in tumor and tumor-draining lymph nodes to suppress tumor growth.
    Xu J; Ma Q; Zhang Y; Fei Z; Sun Y; Fan Q; Liu B; Bai J; Yu Y; Chu J; Chen J; Wang C
    Nat Commun; 2022 Jan; 13(1):110. PubMed ID: 35013252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
    Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
    J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
    Fransen MF; Schoonderwoerd M; Knopf P; Camps MG; Hawinkels LJ; Kneilling M; van Hall T; Ossendorp F
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
    O'Melia MJ; Manspeaker MP; Thomas SN
    Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled release of manganese and magnesium ions by microsphere-encapsulated hydrogel enhances cancer immunotherapy.
    Ma L; Wang X; Wu Y; Zhang Y; Yuan X; Mao J; Li Q; Gong S
    J Control Release; 2024 Aug; 372():682-698. PubMed ID: 38950681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
    J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The primordial differentiation of tumor-specific memory CD8
    Huang Q; Wu X; Wang Z; Chen X; Wang L; Lu Y; Xiong D; Liu Q; Tian Y; Lin H; Guo J; Wen S; Dong W; Yang X; Yuan Y; Yue Z; Lei S; Wu Q; Ran L; Xie L; Wang Y; Gao L; Tian Q; Zhou X; Sun B; Xu L; Tang Z; Ye L
    Cell; 2022 Oct; 185(22):4049-4066.e25. PubMed ID: 36208623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation.
    Kim GB; Sung HD; Nam GH; Kim W; Kim S; Kang D; Lee EJ; Kim IS
    J Control Release; 2021 May; 333():328-338. PubMed ID: 33794271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
    Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy.
    Ding M; Fan Y; Lv Y; Liu J; Yu N; Kong D; Sun H; Li J
    Acta Biomater; 2022 Sep; 149():334-346. PubMed ID: 35779775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injectable Micelle-Incorporated Hydrogels for the Localized Chemo-Immunotherapy of Breast Tumors.
    Qin X; He L; Feng C; Fan D; Liang W; Wang Q; Fang J
    ACS Appl Mater Interfaces; 2021 Oct; 13(39):46270-46281. PubMed ID: 34550685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.